Suppr超能文献

利用丙氨酸扫描诱变和分子动力学模拟表征RON-MSPβ复合物形成过程中的热点

Characterizing the Hot Spots Involved in RON-MSPβ Complex Formation Using Alanine Scanning Mutagenesis and Molecular Dynamics Simulation.

作者信息

Zarei Omid, Hamzeh-Mivehroud Maryam, Benvenuti Silvia, Ustun-Alkan Fulya, Dastmalchi Siavoush

机构信息

Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.

Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

出版信息

Adv Pharm Bull. 2017 Apr;7(1):141-150. doi: 10.15171/apb.2017.018. Epub 2017 Apr 13.

Abstract

Implication of protein-protein interactions (PPIs) in development of many diseases such as cancer makes them attractive for therapeutic intervention and rational drug design. RON (Recepteur d'Origine Nantais) tyrosine kinase receptor has gained considerable attention as promising target in cancer therapy. The activation of RON via its ligand, macrophage stimulation protein (MSP) is the most common mechanism of activation for this receptor. The aim of the current study was to perform in silico alanine scanning mutagenesis and to calculate binding energy for prediction of hot spots in protein-protein interface between RON and MSPβ chain (MSPβ). In this work the residues at the interface of RON-MSPβ complex were mutated to alanine and then molecular dynamics simulation was used to calculate binding free energy. The results revealed that Gln, Arg, Glu, Pro, Glu, and His residues from RON and Arg, His, Ser, Glu, and Arg from MSPβ may play important roles in protein-protein interaction between RON and MSP. Identification of these RON hot spots is important in designing anti-RON drugs when the aim is to disrupt RON-MSP interaction. In the same way, the acquired information regarding the critical amino acids of MSPβ can be used in the process of rational drug design for developing MSP antagonizing agents, the development of novel MSP mimicking peptides where inhibition of RON activation is required, and the design of experimental site directed mutagenesis studies.

摘要

蛋白质-蛋白质相互作用(PPI)在包括癌症在内的多种疾病发展过程中的作用,使其成为治疗干预和合理药物设计的有吸引力的靶点。RON(源自南特的受体)酪氨酸激酶受体作为癌症治疗中有前景的靶点已受到相当多的关注。RON通过其配体巨噬细胞刺激蛋白(MSP)激活是该受体最常见的激活机制。本研究的目的是进行计算机丙氨酸扫描诱变,并计算结合能以预测RON与MSPβ链(MSPβ)之间蛋白质-蛋白质界面中的热点。在这项工作中,RON-MSPβ复合物界面处的残基被突变为丙氨酸,然后使用分子动力学模拟来计算结合自由能。结果表明,RON中的Gln、Arg、Glu、Pro、Glu和His残基以及MSPβ中的Arg、His、Ser、Glu和Arg残基可能在RON与MSP之间的蛋白质-蛋白质相互作用中起重要作用。当目的是破坏RON-MSP相互作用时,识别这些RON热点在设计抗RON药物中很重要。同样,关于MSPβ关键氨基酸的获得信息可用于合理药物设计过程中,以开发MSP拮抗剂、开发需要抑制RON激活的新型MSP模拟肽以及设计实验性位点定向诱变研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/03a5/5426727/28f8a922006c/apb-7-141-g001.jpg

相似文献

3
Crystal structure of the Sema-PSI extracellular domain of human RON receptor tyrosine kinase.
PLoS One. 2012;7(7):e41912. doi: 10.1371/journal.pone.0041912. Epub 2012 Jul 25.
8
Curcumin blocks RON tyrosine kinase-mediated invasion of breast carcinoma cells.
Cancer Res. 2008 Jul 1;68(13):5185-92. doi: 10.1158/0008-5472.CAN-07-6883.
10
Characterization of two monoclonal antibodies against the RON tyrosine kinase receptor.
Hybridoma. 1998 Dec;17(6):541-51. doi: 10.1089/hyb.1998.17.541.

引用本文的文献

1
Identification of Novel Mutations in DOF 4.2 Coding Gene.
Adv Pharm Bull. 2021 May;11(3):557-563. doi: 10.34172/apb.2021.064. Epub 2020 May 9.
3
Identification of the retinoschisin-binding site on the retinal Na/K-ATPase.
PLoS One. 2019 May 2;14(5):e0216320. doi: 10.1371/journal.pone.0216320. eCollection 2019.
4
Insight Into the Binding Mechanism of p53/pDIQ-MDMX/MDM2 With the Interaction Entropy Method.
Front Chem. 2019 Jan 29;7:33. doi: 10.3389/fchem.2019.00033. eCollection 2019.
5
dbMPIKT: a database of kinetic and thermodynamic mutant protein interactions.
BMC Bioinformatics. 2018 Nov 27;19(1):455. doi: 10.1186/s12859-018-2493-7.

本文引用的文献

1
Protein-protein interaction inhibitors: advances in anticancer drug design.
Expert Opin Drug Discov. 2016 Oct;11(10):957-68. doi: 10.1080/17460441.2016.1223038. Epub 2016 Sep 2.
2
Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.
J Cancer Res Clin Oncol. 2016 Dec;142(12):2429-2446. doi: 10.1007/s00432-016-2214-4. Epub 2016 Aug 8.
3
Molecular docking as a popular tool in drug design, an in silico travel.
Adv Appl Bioinform Chem. 2016 Jun 28;9:1-11. doi: 10.2147/AABC.S105289. eCollection 2016.
4
Bifunctional Ligands for Inhibition of Tight-Binding Protein-Protein Interactions.
Bioconjug Chem. 2016 Aug 17;27(8):1900-10. doi: 10.1021/acs.bioconjchem.6b00293. Epub 2016 Jul 20.
5
Cancer treatment and survivorship statistics, 2016.
CA Cancer J Clin. 2016 Jul;66(4):271-89. doi: 10.3322/caac.21349. Epub 2016 Jun 2.
6
Peptides and Peptide Analogs to Inhibit Protein-Protein Interactions.
Adv Exp Med Biol. 2016;917:147-83. doi: 10.1007/978-3-319-32805-8_8.
7
Interaction Entropy: A New Paradigm for Highly Efficient and Reliable Computation of Protein-Ligand Binding Free Energy.
J Am Chem Soc. 2016 May 4;138(17):5722-8. doi: 10.1021/jacs.6b02682. Epub 2016 Apr 20.
8
Recent developments in receptor tyrosine kinases targeted anticancer therapy.
Vet World. 2016 Jan;9(1):80-90. doi: 10.14202/vetworld.2016.80-90. Epub 2016 Jan 29.
9
A Thousand and One Receptor Tyrosine Kinases: Wherein the Specificity?
Curr Top Dev Biol. 2016;117:393-404. doi: 10.1016/bs.ctdb.2015.10.016. Epub 2016 Jan 7.
10
Novel binding patterns between ganoderic acids and neuraminidase: Insights from docking, molecular dynamics and MM/PBSA studies.
J Mol Graph Model. 2016 Apr;65:27-34. doi: 10.1016/j.jmgm.2016.02.006. Epub 2016 Feb 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验